OrbiMed’s Pacira BioSciences PCRX Stock Holding History

OrbiMed’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-176,000	Closed	-$15.6M	–	146
2015 Q1	$15.6M	Hold	176,000	–	–	0.13%	88
2014 Q4	$15.6M	Sell	176,000 -61,900	-26%	-$5.86M	0.15%	83
2014 Q3	$23.1M	Buy	+237,900	New	+$23.1M	0.24%	68
2013 Q3	–	Sell	-498,000	Closed	-$14.4M	–	131
2013 Q2	$14.4M	Buy	+498,000	New	+$14.4M	0.31%	61

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed's PCRX Position: Q2 2015 in Review

OrbiMed sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 176,000 shares — an estimated $15.6M sold.

OrbiMed first reported a position in PCRX in Q2 2013 and held it in 4 quarters. The position peaked at $23.1M in Q3 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

OrbiMed reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
OrbiMed sold 176,000 Pacira BioSciences shares in Q2 2015, an estimated $15.6M.
OrbiMed first reported a position in Pacira BioSciences in Q2 2013 and held it in 4 quarters.
OrbiMed's Pacira BioSciences position peaked at $23.1M in Q3 2014.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.